Top

Published in:

Open Access 01-04-2015 | Review

Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review

Authors: Aleksandra Duda-Chodak, Tomasz Tarko, Paweł Satora, Paweł Sroka

Published in: European Journal of Nutrition | Issue 3/2015

Abstract

The intestinal microbiome plays an important role in the metabolism of chemical compounds found within food. Bacterial metabolites are different from those that can be generated by human enzymes because bacterial processes occur under anaerobic conditions and are based mainly on reactions of reduction and/or hydrolysis. In most cases, bacterial metabolism reduces the activity of dietary compounds; however, sometimes a specific product of bacterial transformation exhibits enhanced properties. Studies on the metabolism of polyphenols by the intestinal microbiota are crucial for understanding the role of these compounds and their impact on our health. This review article presents possible pathways of polyphenol metabolism by intestinal bacteria and describes the diet-derived bioactive metabolites produced by gut microbiota, with a particular emphasis on polyphenols and their potential impact on human health. Because the etiology of many diseases is largely correlated with the intestinal microbiome, a balance between the host immune system and the commensal gut microbiota is crucial for maintaining health. Diet-related and age-related changes in the human intestinal microbiome and their consequences are summarized in the paper.

Hooper LV, Gordon JI (2001) Commensal host-bacterial relationships in the gut. Science 292:1115–1118. doi:10.1126/science.1058709

O’Hara AM, Shanahan F (2006) The gut flora as a forgotten organ. EMBO Rep 7(7):688–693. doi:10.1038/sj.embor.7400731

Hattori M, Taylor TD (2009) The human intestinal microbiome: a new frontier of human biology. DNA Res 16:1–12. doi:10.1093/dnares/dsn033

Zhu B, Wang X, Li L (2010) Human gut microbiome: the second genome of human body. Protein Cell 1(8):718–725. doi:10.1007/s13238-010-0093-z

Sakata H, Yoshioka H, Fujita K (1985) Development of the intestinal flora in very low birth weight infants compared to normal full-term newborns. Eur J Pediatr 144:186–190. doi:10.1203/01.PDR.0000078274.74607.7A

Fanaro S, Chierici R, Guerrini P, Vigi V (2003) Intestinal microflora in early infancy: composition and development. Acta Paediatr Suppl 441:48–55. doi:10.1111/j.1651-2227.2003.tb00646.x

Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE (2006) Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 118(2):511–521. doi:10.1542/peds.2005-2824

Zoetendal EG, Akkermans AD, De Vos WM (1998) Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 64(10):3854–3859

Brown K, DeCoffe D, Molcan E, Gibson DL (2012) Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 4(8):1095–1119. doi:10.3390/nu4081095

10.

Salminen S, Gibson GR, McCartney AL, Isolauri E (2004) Influence of mode of delivery on gut microbiota composition in seven year old children. Gut 53(9):1388–1389. doi:10.1136/gut.2004.041640

11.

Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R (2010) Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 107(26):11971–11975. doi:10.1073/pnas.1002601107

12.

Hakansson A, Molin G (2011) Gut microbiota and inflammation. Nutrients 3(6):637–682. doi:10.3390/nu3060637

13.

Whitman WB, Coleman DC, Wiebe WJ (1998) Prokaryotes: the unseen majority. Proc Natl Acad Sci USA 95:6578–6583. doi:10.1073/pnas.95.12.6578

14.

Dicksved J (2008) Exploring the human intestinal microbiome in health and disease. Dissertation, Thesis Swedish University of Agricultural Sciences, Acta Universitatis Agriculturae Sueciae 2008:30. Uppsala. http://pub.epsilon.slu.se/1760/1/Dicksved_Thesis_Kappan.pdf Accessed 24 Apr 2014

15.

Saarela M, Lähteenmäki L, Crittenden R, Salminen S, Mattila-Sandholm T (2002) Gut bacteria and health foods—the European perspective. Int J Food Microbiol 78:99–117. doi:10.1016/S0168-1605(02)00235-0

16.

Del Rio D, Rodriguez-Mateos A, Spencer JPE, Tognolini M, Borges G, Crozier A (2013) Dietary (poly) phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal 18(14):1818–1892. doi:10.1089/ars.2012.4581

17.

Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA (2005) Diversity of the human intestinal microbial flora. Science 308(5728):1635–1638. doi:10.1126/science.1110591

18.

Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L (2008) Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS ONE 3(7):e2836. doi:10.1371/journal.pone.0022109

19.

Lagier JC, Million M, Hugon P, Armougom F, Raoult D (2012) Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol 2:136. doi:10.3389/fcimb.2012.00136 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487222/ Accessed 19 Dec 2014

20.

Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, MetaHIT Consortium, Bork P, Ehrlich SD, Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59–65. doi:10.1038/nature08821

21.

Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R (2004) Use of 16S rRNA gene-targeted group-specific primers for Real-Time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol 70(12):7220–7228. doi:10.1128/AEM.70.12.7220-7228.2004

22.

Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104:13780–13785. doi:10.1073/pnas.0706625104

23.

Hayashi H, Takahashi R, Nishi T, Sakamoto M, Benno Y (2005) Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism. J Med Microbiol 54(Pt 11):1093–1101. doi:10.1099/jmm.0.45935-0

24.

Wang M, Ahrné S, Jeppsson B, Molin G (2005) Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes. FEMS Microbiol Ecol 54(2):219–231. doi:10.1016/j.femsec.2005.03.012

25.

Jeffery IB, O’Toole PW (2013) Diet-microbiota interactions and their implications for healthy living. Nutrients 5(1):234–252. doi:10.3390/nu5010234

26.

Mariat D, Firmesse O, Levenez F, Guimarăes V, Sokol H, Doré J, Corthier G, Furet JP (2009) The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 9:123. doi:10.1186/1471-2180-9-123. http://www.biomedcentral.com/1471-2180/9/123. Accessed 12 Apr 2014

27.

Agans A, Rigsbee L, Kenche H, Michail S, Khamis HJ, Paliy O (2011) Distal gut microbiota of adolescent children is different from that of adults. FEMS Microbiol Ecol 77:404–412. doi:10.1111/j.1574-6941.2011.01120.x

28.

Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444(7122):1022–1023. doi:10.1038/4441022a

29.

De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P (2011) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 107(33):14691–14696. doi:10.1073/pnas.1005963107

30.

Laparra JM, Sanz Y (2010) Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 61(3):219–225. doi:10.1016/j.phrs.2009.11.001

31.

Duda-Chodak A (2012) The inhibitory effect of polyphenols on human gut microbiota. J Physiol Pharmacol 63(5):497–503

32.

Collado MC, Calabuig M, Sanz Y (2007) Differences between the fecal microbiota of coeliac infants and healthy controls. Curr Issues Intest Microbiol 8(1):9–14

33.

Sanz Y (2010) Effects of a gluten-free diet on gut microbiota and immune function in healthy adult humans. Gut Microbes 1(3):135–137. doi:10.4161/gmic.1.3.11868

34.

Gibson GR (2008) Prebiotics as gut microflora management tools. J Clin Gastroenterol 42(Suppl 2):S75–S79. doi:10.1097/MCG.0b013e31815ed097

35.

Moshfegh AJ, Friday JE, Goldman JP, Ahuja JK (1999) Presence of inulin and oligofructose in the diets of Americans. J Nutr 129(7 Suppl):1407S–1411S

36.

Rigon G, Vallone C, Lucantoni V, Signore F (2012) Maternal factors pre- and during delivery contribute to gut microbiota shaping in newborns. Front Cell Infect Microbiol 2:93. doi:10.3389/fcimb.2012.00093. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417649/ Accessed 24 Apr 2014

37.

Hehemann JH, Correc G, Barbeyron T, Helbert W, Czjzek M, Michel G (2010) Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature 464(7290):908–912. doi:10.1038/nature08937

38.

Kurokawa K, Itoh T, Kuwahara T, Oshima K, Toh H, Toyoda A, Takami H, Morita H, Sharma VK, Srivastava TP, Taylor TD, Noguchi H, Mori H, Ogura Y, Ehrlich DS, Itoh K, Takagi T, Sakaki Y, Hayashi T, Hattori M (2007) Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res 14(4):169–181. doi:10.1093/dnares/dsm018

39.

Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD (2009) High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137(5):1716–1724. doi:10.1053/j.gastro.2009.08.042

40.

Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1(6):6ra14. doi:10.1126/scitranslmed.3000322

41.

Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334(6052):105–108. doi:10.1126/science.1208344

42.

Santacruz A, Marcos A, Wärnberg J, Martí A, Martin-Matillas M, Campoy C, Moreno LA, Veiga O, Redondo-Figuero C, Garagorri JM, Azcona C, Delgado M, García-Fuentes M, Collado MC, Sanz Y; EVASYON Study Group (2009) Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring) 17(10):1906–1915. doi:10.1038/oby.2009.112

43.

Ismail NA, Ragab SH, ElBaky AA, Shoeib ARS, Alhosary Y, Fekry D (2011) Frequency of Firmicutes and Bacteroidetes in gut microbiota in obese and normal weight Egyptian children and adults. Arch Med Sci 7(3):501–507. doi:10.5114/aoms.2011.23418

44.

Green CJ (2001) Fibre in enteral nutrition. Clin Nutr 20(Suppl. 1):23–39. doi:10.1054/clnu.2001.0425

45.

Zimmer J, Lange B, Frick JS, Sauer H, Zimmermann K, Schwiertz A, Rusch K, Klosterhalfen S, Enck P (2012) A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 66:53–60. doi:10.1038/ejcn.2011.141

46.

Peterson J, Dwyer J, Bhagwat S, Haytowit D, Holden J, Eldridge AL, Beecher G, Aladesanmi J (2005) Major flavonoids in dry tea. J Food Compost Anal 18:487–501. doi:10.1016/j.jfca.2004.05.006

47.

Ankolekar C, Johnson D, Pinto Mda S, Johnson K, Labbe R, Shetty K (2011) Inhibitory potential of tea polyphenolics and influence of extraction time against Helicobacter pylori and lack of inhibition of beneficial lactic acid bacteria. J Med Food 14(11):1321–1329. doi:10.1089/jmf.2010.0237

48.

Shin JS, Chung HS (2007) Antibacterial activities of phenolic components from Camellia sinensis L. on pathogenic microorganisms. J Food Sci Nutr 12:135–140. doi:10.3746/jfn.2007.12.3.135

49.

Nakayama M, Shigemune N, Tsugukuni T, Jun H, Matsushita T, Mekada Y, Kurahachi M, Miyamoto T (2012) Mechanism of the combined anti-bacterial effect of green tea extract and NaCl against Staphylococcus aureus and Escherichia coli O157:H7. Food Control 25(1):225–232. doi:10.1016/j.foodcont.2011.10.021

50.

Kohda C, Yanagawa Y, Shimamura T (2008) Epigallocatechin gallate inhibits intracellular survival of Listeria monocytogenes in macrophages. Biochem Biophys Res Commun 365(2):310–315. doi:10.1016/j.bbrc.2007.10.190

51.

Si W, Gong J, Tsao R, Kalab M, Yang R, Yin Y (2006) Bioassay-guided purification and identification of antimicrobial components in Chinese green tea extract. J Chromatogr A 1125(2):204–210. doi:10.1016/j.chroma.2006.05.061

52.

Bancirova M (2010) Comparison of the antioxidant capacity and the antimicrobial activity of black and green tea. Food Res Int 43:1379–1382. doi:10.1016/j.foodres.2010.04.020

53.

Chen YL, Tsai HL, Peng CW (2012) EGCG debilitates the persistence of EBV latency by reducing the DNA binding potency of nuclear antigen 1. Biochem Biophys Res Commun 417(3):1093–1099. doi:10.1016/j.bbrc.2011.12.104

54.

Nakayama M, Suzuki K, Toda M, Okubo S, Hara Y, Shimamura T (1993) Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res 21(4):289–299

55.

Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath AK, Wu S, Jiang S (2005) Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 1723(1–3):270–281. doi:10.1016/j.bbagen.2005.02.012

56.

Hamza A, Zhan CG (2006) How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. J Phys Chem B 110(6):2910–2917. doi:10.1021/jp0550762

57.

Williamson MP, McCormick TG, Nance CL, Shearer WT (2006) Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J Allergy Clin Immunol 118(6):1369–1374. doi:10.1016/j.jaci.2006.08.016

58.

Park BJ, Park JC, Taguchi H, Fukushima K, Hyon SH, Takatori K (2006) Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Biochem Biophys Res Commun 347(2):401–405. doi:10.1016/j.bbrc.2006.06.037

59.

Lee HC, Jenner AM, Low CS, Lee YK (2006) Effect of tea phenolics and their aromatic fecal bacterial metabolites on intestinal microbiota. Res Microbiol 157(9):876–984. doi:10.1016/j.resmic.2006.07.004

60.

Bae EA, Han MJ, Kim DH (1999) In vitro anti-Helicobacter pylori activity of some flavonoids and their metabolites. Planta Med 65(5):442–443. doi:10.1055/s-2006-960805

61.

Parkar SG, Stevenson DE, Skinner MA (2008) The potential influence of fruit polyphenols on colonic microflora and human gut health. Int J Food Microbiol 124(3):295–298. doi:10.1016/j.ijfoodmicro.2008.03.017

62.

Rodríguez Vaquero MJ, Alberto MR, Manca de Nadra MC (2007) Antibacterial effect of phenolic compounds from different wines. Food Control 18:93–101. doi:10.1111/j.1745-4514.2011.00648.x

63.

Tzounis X, Vulevic J, Kuhnle GG, George T, Leonczak J, Gibson GR, Kwik-Uribe C, Spencer JP (2008) Flavanol monomer-induced changes to the human faecal microflora. Br J Nutr 99(4):782–792. doi:10.1017/S0007114507853384

64.

Smith AH, Zoetendal E, Mackie RI (2005) Bacterial mechanisms to overcome inhibitory effects of dietary tannins. Microb Ecol 50:197–205. doi:10.1007/s00248-004-0180-x

65.

Dolara P, Luceri C, De Filippo C, Femia AP, Giovannelli L, Caderni G, Cecchini C, Silvi S, Orpianesi C, Cresci A (2005) Red wine polyphenols influence carcinogenesis, intestinal microflora, oxidative damage and gene expression profiles of colonic mucosa in F344 rats. Mutat Res 591(1–2):237–246. doi:10.1016/j.mrfmmm.2005.04.022

66.

Sanchez-Patan F, Cueva C, Monagas M, Walton GE, Gibson GR, Quintanilla-López JE, Lebrón-Aguilar R, Martín-Álvarez PJ, Moreno-Arribas MV, Bartolomé B (2012) In vitro fermentation of a red wine extract by human gut microbiota: changes in microbial groups and formation of phenolic metabolites. J Agric Food Chem 60:2136–2147. doi:10.1021/jf2040115

67.

Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R, Cardona Diaz F, Andrés-Lacueva C, Tinahones FJ (2012) Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr 95(6):1323–1334. doi:10.3945/ajcn.111.027847

68.

Bustos I, García-Cayuela T, Hernández-Ledesma B, Peláez C, Requena T, Martínez-Cuesta MC (2012) Effect of flavan-3-ols on the adhesion of potential probiotic lactobacilli to intestinal cells. J Agric Food Chem 60(36):9082–9088. doi:10.1021/jf301133g

69.

Puupponen-Pimiä R, Nohynek L, Meier C, Kähkönen M, Heinonen M, Hopia A, Oksman-Caldentey KM (2001) Antimicrobial properties of phenolic compounds from berries. J Appl Microbiol 90(4):494–507. doi:10.1046/j.1365-2672.2001.01271.x

70.

Kim SH, Park M, Woo H, Tharmalingam N, Lee G, Rhee KJ, Eom YB, Han SI, Seo WD, Kim JB (2012) Inhibitory effects of anthocyanins on secretion of Helicobacter pylori CagA and VacA toxins. Int J Med Sci 9(10):838–842. doi:10.7150/ijms.5094

71.

Hidalgo M, Oruna-Concha MJ, Kolida S, Walton GE, Kallithraka S, Spencer JP, de Pascual-Teresa S (2012) Metabolism of anthocyanins by human gut microflora and their influence on gut bacterial growth. J Agric Food Chem 60(15):3882–3890. doi:10.1021/jf3002153

72.

Vivas N, Lonvaud-Funel A, Glories Y (1997) Effect of phenolic acids and anthocyanins on growth, viability and malolactic activity of a lactic acid bacterium. Food Microbiol 14:291–300. doi:10.1006/fmic.1996.0086

73.

Howell AB (2007) Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res 51:732–737. doi:10.1002/mnfr.200700038

74.

Foo LY, Lu Y, Howell AB, Vorsa N (2000) The structure of cranberry proanthocyanidins which inhibit adherence of uropathogenic P-fimbriated Escherichia coli in vitro. Phytochemistry 54:173–181. doi:10.1016/S0031-9422(99)00573-7

75.

Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M (2005) A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry 66(18):2281–2291. doi:10.1016/j.phytochem.2005.05.022

76.

Candela M, Maccaferri S, Turroni S, Carnevali P, Brigidi P (2010) Functional intestinal microbiome, new frontiers in prebiotic design. Int J Food Microbiol 140:93–101. doi:10.1016/j.ijfoodmicro.2010.04.017

77.

Flint HJ (2012) The impact of nutrition on the human microbiome. Nutr Rev 70(Suppl 1):S10–S13. doi:10.1111/j.1753-4887.2012.00499.x

78.

Flint HJ, Scott KP, Duncan SH, Louis P, Forano E (2012) Microbial degradation of complex carbohydrates in the gut. Gut Microbes 3(4):289–306. doi:10.4161/gmic.19897

79.

Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 17(12):1519–1528. doi:10.3748/wjg.v17.i12.1519

80.

Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco MJ, Léotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A (2010) Prebiotic effects: metabolic and health benefits. Br J Nutr 104(Suppl. 2):S1–S63. doi:10.1017/S0007114510003363

81.

Gibson GR, Roberfroid MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125(6):1401–1412

82.

Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB (2004) Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 17:259–275. doi:10.1079/NRR200479

83.

Ito M, Deguchi Y, Matsumoto K, Kimura M, Onodera N, Yajima T (1993) Influence of galactooligosaccharides on the human fecal microflora. J Nutr Sci Vitaminol (Tokyo) 39(6):635–640

84.

Rowland IR, Tanaka R (1993) The effects of transgalactosylated oligosaccharides on gut flora metabolism in rats associated with a human faecal microflora. J Appl Bacteriol 74(6):667–674. doi:10.1111/j.1365-2672.1993.tb05201.x

85.

Bouhnik Y, Flourié B, D’Agay-Abensour L, Pochart P, Gramet G, Duran M, Rambaud J-C (1997) Administration of trans-galacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nutr 127:444–448

86.

Boehm G, Lidestri M, Casetta P, Jelinek J, Negretti F, Stahl B, Marini A (2002) Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of fecal bifidobacteria in preterm infants. Arch Dis Child Fetal Neonatal Ed 86(3):F178–F181. doi:10.1136/fn.86.3.F178

87.

Ito Y, Moriwaki H, Muto Y, Kato N, Watanabe K, Ueno K (1997) Effect of lactulose on short-chain fatty acids and lactate production and on the growth of faecal flora, with special reference to Clostridium difficile. J Med Microbiol 46(1):80–84. doi:10.1099/00222615-46-1-80

88.

Gibson GR, Beatty ER, Wang X, Cummings JH (1995) Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108(4):975–982. doi:10.1016/0016-5085(95)90192-2

89.

Kleessen B, Sykura B, Zunft HJ, Blaut M (1997) Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr 65(5):1397–1402

90.

Langlands SJ, Hopkins MJ, Coleman N, Cummings JH (2004) Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 53(11):1610–1616. doi:10.1136/gut.2003.037580

91.

Duncan SH, Louis P, Flint HJ (2004) Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microbiol 70(10):5810–5817. doi:10.1128/AEM.70.10.5810-5817

92.

Belenguer A, Duncan SH, Calder AG, Holtrop G, Louis P, Lobley GE, Flint HJ (2006) Two routes of metabolic cross-feeding between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ Microbiol 72(5):3593–3599. doi:10.1128/AEM.72.5.3593-3599.2006

93.

Kankaanpää P, Yang B, Kallio H, Isolauri E, Salminen S (2004) Effects of polyunsaturated fatty acids in growth medium on lipid composition and on physicochemical surface properties of lactobacilli. Appl Environ Microbiol 70(1):129–136. doi:10.1128/AEM.70.1.129-136.2004

94.

Gorissen L, De Vuyst L, Raes K, De Smet S, Leroy F (2012) Conjugated linoleic and linolenic acid production kinetics by bifidobacteria differ among strains. Int J Food Microbiol 155(3):234–240. doi:10.1016/j.ijfoodmicro.2012.02.012

95.

Wahle KW, Heys SD, Rotondo D (2004) Conjugated linoleic acids: are they beneficial or detrimental to health? Prog Lipid Res 43(6):553–587. doi:10.1016/j.plipres.2004.08.002

96.

Ross RP, Mills S, Hill C, Fitzgerald GF, Stanton C (2010) Specific metabolite production by gut microbiota as a basis for probiotic function. Int Dairy J 20(4):269–276. doi:10.1016/j.idairyj.2009.12.003

97.

Possemiers S, Bolca S, Verstraete W, Heyerick A (2011) The intestinal microbiome: a separate organ inside the body with the metabolic potential to influence the bioactivity of botanicals. Fitoterapia 82:53–66. doi:10.1016/j.fitote.2010.07.012

98.

Hervert-Hernández D, Goñi I (2011) Dietary polyphenols and human gut microbiota: a review. Food Rev Int 27(2):154–169. doi:10.1080/87559129.2010.535233

99.

Young IS, Woodside JV (2001) Antioxidants in health and disease. J Clin Pathol 54:176–186. doi:10.1136/jcp.54.3.176

100.

Willcox JK, Ash SL, Catignani GL (2004) Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr 44:275–295. doi:10.1080/10408690490468489

101.

Zafra-Stone S, Yasmin T, Bagchi M, Chatterjee A, Vinson JA, Bagchi D (2007) Berry anthocyanins as novel antioxidants in human health and disease prevention. Mol Nutr Food Res 51(6):675–683. doi:10.1002/mnfr.200700002

102.

Wang LS, Stoner GD (2008) Anthocyanins and their role in cancer prevention. Cancer Lett 269(2):281–290. doi:10.1016/j.canlet.2008.05.020

103.

Wang XL, Kim HJ, Kang SI, Kim SI, Hur HG (2007) Production of phytoestrogen S-equol from daidzein in mixed culture of two anaerobic bacteria. Arch Microbiol 187(2):155–160. doi:10.1007/s00203-006-0183-8

104.

Yokoyama S, Niwa T, Osawa T, Suzuki T (2010) Characterization of an O-desmethylangolensin-producing bacterium isolated from human feces. Arch Microbiol 192(1):15–22. doi:10.1007/s00203-009-0524-5

105.

Yokoyama S, Suzuki T (2008) Isolation and characterization of a novel equol-producing bacterium from human feces. Biosci Biotechnol Biochem 72(10):2660–2666. doi:10.1271/bbb.80329

106.

Matthies A, Blaut M, Braune A (2009) Isolation of a human intestinal bacterium capable of daidzein and genistein conversion. Appl Environ Microbiol 75(6):1740–1744. doi:10.1128/AEM.01795-08

107.

Raimondi S, Roncaglia L, De Lucia M, Amaretti A, Leonardi A, Pagnoni UM, Rossi M (2009) Bioconversion of soy isoflavones daidzin and daidzein by Bifidobacterium strains. Appl Microbiol Biotechnol 81(5):943–950. doi:10.1007/s00253-008-1719-4

108.

Setchell KD, Clerici C (2010) Equol: history, chemistry, and formation. J Nutr 140(7):1355S–1362S. doi:10.3945/jn.109.119776

109.

Setchell KD, Clerici C (2010) Equol: pharmacokinetics and biological actions. J Nutr 140(7):1363S–1368S. doi:10.3945/jn.109.119784

110.

Frankenfeld CL, Atkinson C, Thomas WK, Gonzalez A, Jokela T, Wähälä K, Schwartz SM, Li SS, Lampe JW (2005) High concordance of daidzein-metabolizing phenotypes in individuals measured 1–3 years apart. Br J Nutr 94(6):873–876. doi:10.1079/BJN20051565

111.

Yuan JP, Wang JH, Liu X (2007) Metabolism of dietary soy isoflavones to equol by human intestinal microflora—implications for health. Mol Nutr Food Res 51(7):765–781. doi:10.1002/mnfr.200600262

112.

Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, Handa RJ, Heubi JE (2005) S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 81(5):1072–1079

113.

Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, Hur HG, Han KO (2006) Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol 101:246–253. doi:10.1016/j.jsbmb.2006.06.020

114.

Chang YC, Nair MG, Nitiss JL (1995) Metabolites of daidzein and genistein and their biological activities. J Nat Prod 58:1901–1905. doi:10.1021/np50126a016

115.

Lund TD, Blake C, Bu L, Hamaker AN, Lephart ED (2011) Equol an isoflavonoid: potential for improved prostate health, in vitro and in vivo evidence. Reprod Biol Endocrinol 9:4. doi:10.1186/1477-7827-9-4 http://www.rbej.com/content/9/1/4 Accessed 19 Dec 2014

116.

Kang NJ, Lee KW, Rogozin EA, Cho YY, Heo YS, Bode AM, Lee HJ, Dong Z (2007) Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem 282(45):32856–32866. doi:10.1074/jbc.M701459200

117.

Zheng W, Zhang Y, Ma D, Shi Y, Liu C, Wang P (2012) (±)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity. J Clin Biochem Nutr 51(1):61–67. doi:10.3164/jcbn.11-54

118.

Kang JS, Yoon YD, Han MH, Han SB, Lee K, Park SK, Kim HM (2007) Equol inhibits nitric oxide production and inducible nitric oxide syn-thase gene expression through down-regulating the activation of Akt. Int Immunopharmacol 7:491–499. doi:10.1016/j.intimp.2006.12.004

119.

Clavel T, Henderson G, Alpert CA, Philippe C, Rigottier-Gois L, Dore J, Blaut M (2005) Intestinal bacterial communities that produce active estrogen-like compounds enterodiol and enterolactone in humans. Appl Environ Microbiol 71:6077–6085. doi:10.1128/AEM.71.10.6077-6085.2005

120.

Landete JM (2012) Plant and mammalian lignans: a review of source, intake, metabolism, intestinal bacteria and health. Food Res Int 46(1):410–424. doi:10.1016/j.foodres.2011.12.023

121.

Högger P (2013) Nutrition-derived bioactive metabolites produced by gut microbiota and their potential impact on human health. Nutr Med 1(1):1 http://www.nume.de/index.php/nume/article/view/1/4. Accessed 24 Apr 2014

122.

Wang LQ (2002) Mammalian phytoestrogens: enterodiol and enterolactone. J Chromatogr B 777(1–2):289–309. doi:10.1016/S1570-0232(02)00281-7

123.

Brunelli E, Minassi A, Appendino G, Moro L (2007) 8-Prenylnaringenin, inhibits estrogen receptor-alpha mediated cell growth and induces apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 107:140–148. doi:10.1016/j.jsbmb.2007.04.003

124.

Nunes C, Almeida L, Laranjinha J (2005) Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC). Implications for Parkinson’s disease. Neurochem Int 47(3):173–182. doi:10.1016/j.neuint.2005.03.005

125.

Nunes C, Almeida L, Laranjinha J (2008) 3,4-Dihydroxyphenylacetic acid (DOPAC) modulates the toxicity induced by nitric oxide in PC-12 cells via mitochondrial dysfunctioning. Neurotoxicology 29(6):998–1007. doi:10.1016/j.neuro.2008.07.003

126.

Nunes C, Barbosa RM, Almeida L, Laranjinha J (2011) Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis. Mol Cell Neurosci 48(1):94–103. doi:10.1016/j.mcn.2011.06.009

127.

Appeldoorn MM, Vincken JP, Aura AM, Hollman PCH, Gruppen H (2009) Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-Dihydroxyphenyl)-γ-valerolactone as the major metabolites. J Agric Food Chem 57(3):1084–1092. doi:10.1021/jf803059z

128.

Galati G, O’Brien PJ (2004) Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med 37(3):287–303. doi:10.1016/j.freeradbiomed.2004.04.034

129.

Bailey DG, Arnold MO, Spence D (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101–110. doi:10.1046/j.1365-2125.1998.00764.x

130.

Castañeda-Ovando A, Pacheco-Hernández M, Páez-Hernández ME, Rodríguez JA, Galán-Vidal CA (2009) Chemical studies of anthocyanins: a review. Food Chem 113(4):859–871. doi:10.1016/j.foodchem.2008.09.001

131.

Faria A, Fernandes I, Norberto S, Mateus N, Calhau C (2014) Interplay between anthocyanins and gut microbiota. J Agric Food Chem 62(29):6898–6902. doi:10.1021/jf501808a

132.

Keppler K, Humpf HU (2005) Metabolism of anthocyanins and their phenolic degradation products by the intestinal microflora. Bioorg Med Chem 13(17):5195–5205. doi:10.1016/j.bmc.2005.05.003

133.

Seeram NP, Bourquin LD, Nair MG (2001) Degradation products of cyanidin glycosides from tart cherries and their bioactivities. J Agric Food Chem 49(10):4924–4929. doi:10.1021/jf0107508

134.

Vitaglione P, Donnarumma G, Napolitano A, Galvano F, Gallo A, Scalfi L, Fogliano V (2007) Protocatechuic acid is the major human metabolite of cyanidin-glucosides. J Nutr 137(9):2043–2048

135.

Masella R, Santangelo C, D’Archivio M, Li Volti G, Giovannini C, Galvano F (2012) Protocatechuic acid and human disease prevention: biological activities and molecular mechanisms. Curr Med Chem 19(18):2901–2917. doi:10.2174/092986712800672102

136.

Wang D, Wei X, Yan X, Jin T, Ling W (2010) Protocatechuic acid, a metabolite of anthocyanins, inhibits monocyte adhesion and reduces atherosclerosis in apolipoprotein E-deficient mice. J Agric Food Chem 58:12722–12728. doi:10.1021/jf103427j

137.

Williamson G, Clifford MN (2010) Colonic metabolites of berry polyphenols: the missing link to biological activity? Br J Nutr 104(Suppl 3):S48–S66. doi:10.1017/S0007114510003946

138.

Bokkenheuser VD, Shacketon CHL, Winter J (1987) Hydrolysis of dietary flavonoid glycosides by strains of intestinal bacteroides from humans. Biochem J 248:953–956

139.

Terao J (2010) Flavonols: Metabolism, Bioavailability, and Health Impacts. In: Fraga CG (ed) Plant phenolics and human health: biochemistry, nutrition, and pharmacology. Wiley Inc, Hoboken, pp 185–196

140.

Forester SC, Waterhouse AL (2010) Gut metabolites of anthocyanins, gallic acid, 3-O-methylgallic acid, and 2,4,6-trihydroxybenzaldehyde, inhibit cell proliferation of Caco-2 cells. J Agric Food Chem 58(9):5320–5327. doi:10.1021/jf9040172

141.

Verzelloni E, Pellacani C, Tagliazucchi D, Tagliaferri S, Calani L, Costa LG, Brighenti F, Borges G, Crozier A, Conte A, Del Rio D (2011) Antiglycative and neuroprotective activity of colon-derived polyphenol catabolites. Mol Nutr Food Res 55(Suppl 1):S35–S43. doi:10.1002/mnfr.201000525

142.

Day AJ, Bao Y, Morgan MR, Williamson G (2000) Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic Biol Med 29(12):1234–1243. doi:10.1016/S0891-5849(00)00416-0

143.

Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, Kobayashi M, Kanayama M, Uchida K, Terao J (2008) Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem 283(14):9424–9434. doi:10.1074/jbc.M706571200

144.

Scholz-Ahrens KE, Ade P, Marten B, Weber P, Timm W, Açil Y, Glüer CC, Schrezenmeir J (2007) Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr 137(3 Suppl 2):838S–846S

145.

LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M (2013) Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 24(2):160–168. doi:10.1016/j.copbio.2012.08.005

146.

LeBlanc JG, de Giori GS, Smid EJ, Hugenholtz J, Sesma F (2007) Folate production by lactic acid bacteria and other food-grade microorganisms. In: Mendez-Vilas A (ed) Communicating current research and educational topics and trends in applied microbiology, microbiology series No. 1, vol 1, Formatex, Badajos, Spain, pp 329–339

147.

Pompei A, Cordisco L, Amaretti A, Zanoni S, Matteuzzi D, Rossi M (2007) Folate production by bifidobacteria as a potential probiotic property. Appl Environ Microbiol 73(1):179–185. doi:10.1128/AEM.01763-06

148.

Rossi M, Amaretti A, Raimondi S (2011) Folate production by probiotic bacteria. Nutrients 3(1):118–134. doi:10.3390/nu3010118

149.

Hill MJ (1997) Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 6(Suppl 1):S43–S45. doi:10.1097/00008469-199703001-00009

150.

Ramotar K, Conly JM, Chubb H, Louie TJ (1984) Production of menaquinones by intestinal anaerobes. J Infect Dis 150(2):213–218. doi:10.1093/infdis/150.2.213

151.

Mathers JC, Fernandez F, Hill MJ, McCarthy PT, Shearer MJ, Oxley A (1990) Dietary modification of potential vitamin K supply from enteric bacterial menaquinones in rats. Br J Nutr 63(3):639–652. doi:10.1079/BJN19900150

152.

Millette M, Dupont C, Archambault D, Lacroix M (2007) Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates. J Appl Microbiol 102(1):274–282. doi:10.1111/j.1365-2672.2006.03044.x

153.

Millette M, Cornut G, Dupont C, Shareck F, Archambault D, Lacroix M (2008) Capacity of human nisin- and pediocin-producing lactic acid bacteria to reduce intestinal colonization by vancomycin-resistant enterococci. Appl Environ Microbiol 74(7):1997–2003. doi:10.1128/AEM.02150-07

154.

Björksten B, Naaber P, Sepp E, Mikelsaar M (1999) The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 29(3):342–346. doi:10.1046/j.1365-2222.1999.00560.x

155.

McGarr SE, Ridlon JM, Hylemon PB (2005) Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol 39(2):98–109

156.

Serra A, Macia A, Romero M, Reguant J, Ortega N, Motilva M (2012) Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem 130:383–393. doi:10.1016/j.foodchem.2011.07.055

157.

Peng X, Zhang Z, Zhang N, Liu L, Li S, Wei H (2014) In vitro catabolism of quercetin by human fecal bacteria and the antioxidant capacity of its catabolites. Food Nutr Res 58:23406. doi:10.3402/fnr.v58.23406

Title: Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review
Authors: Aleksandra Duda-Chodak
Tomasz Tarko
Paweł Satora
Paweł Sroka
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nutrition / Issue 3/2015
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-015-0852-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Intracellular receptor regulation of adipose metabolism by the isoflavone genistein

Pomegranate and green tea extracts protect against ER stress induced by a high-fat diet in skeletal muscle of mice

Association between different obesity measures and the risk of stroke in the EPIC Spanish cohort

Dietary glycemic index, glycemic load and risk of age-related cataract extraction: a case–control study in Italy

Effects of regular consumption of different forms of almonds and hazelnuts on acceptance and blood lipids

Low-dose B vitamins supplementation ameliorates cardiovascular risk: a double-blind randomized controlled trial in healthy Chinese elderly

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage